Apyx Medical Corporation (NASDAQ:APYX) is one of the high-growth micro-cap stocks to buy now. On May 21, Apyx Medical Corporation (NASDAQ:APYX) announced new clinical data in Aesthetic Surgery Journal Open Forum highlighting a promising approach to treating cellulite and skin laxity, two common concerns among women.
Pixabay / Public Domain
The results were part of a clinical study evaluating a combination treatment approach utilizing Avéli for targeted subcision to disrupt fibrous septae, followed by Renuvion to reduce skin laxity. The study was conducted through controlled helium plasma radiofrequency energy.
Conducted in 22 patients, the study showed that 81.8% of patients improved cellulite, with 3D imaging demonstrating measurable reductions in dimple volume. The study results affirmed that a combination of Aveli and Renuvion is effective in addressing the structural cause of dimpling and the quality of the skin itself. According to Barry E. DiBernardo, MD, lead investigator of the study, the findings add to growing evidence that affirms complementary treatment approaches.
Apyx Medical Corporation (NASDAQ:APYX) is an advanced energy technology company that develops, manufactures, and markets medical devices for the cosmetic and surgical markets. They are best known for their proprietary Helium Plasma Technology, which provides surgeons with highly precise, controlled heat for cutting, coagulating, and contracting soft tissue.
While we acknowledge the potential of APYX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Billionaire Ken Fisher’s Top 12 High-Growth Stock Picks and 12 Best Tech Stocks to Invest In on the Dip.
Disclosure: None. Follow Insider Monkey on Google News.